Information Library
Results for: Cardiovascular - High-quality studies
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
The Contribution of Early-phase Clinical Data to a Drug’s Integrated Cardiac Safety Portfolio
Hear from the Experts — January 16, 2012
This article examines the financial and time benefits to incorporating intensive ECG and QT/QTc monitoring in early-phase clinical studies. -
The Contribution of Early-phase Clinical Data to a Drug’s Integrated Cardiac Safety Portfolio
Hear from the Experts — December 6, 2011
This article examines the financial and time benefits to incorporating intensive ECG and QT/QTc monitoring in early-phase clinical studies. -
CardioCheck
White Paper — May 10, 2011
Quintiles' CardioCheck program is designed to provide rapid insight into potential cardiotoxic influences of pharmaceutical compounds. -
Clinical Endpoint Committees - Summary
White Paper — March 6, 2011
What are regulatory boards looking for in clinical endpoint committees? Read our executive summary on the current best practice across the industry. -
Clinical Endpoint Committees
White Paper — February 22, 2011
As regulatory boards are expecting more from clinical endpoint committees, what guidance can you follow? This white paper sets forth current best practice for CECs. -
Clinical – Smarter Trials, Accelerated Outcomes
Brochure — February 16, 2011
Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues. -
Quintiles Speeds Early-Phase Decision Making with New Unit in Hyderabad, India
Press Release — January 24, 2011 – Quintiles officially opened its new Phase I research facility in Hyderabad, India at Apollo Health City.
-
Regulatory Landscapes for Future Antidiabetic Drug Development
Hear from the Experts — May 12, 2010
In the March 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the EMA Guidance on diabetes drugs and cardiovascular risk. -
NHS Motivating Patients
Case Study — May 7, 2010
In 2008, the NHS announced plans to offer free health checks for heart disease, stroke, diabetes and kidney disease. Learn why Quintiles was the right ally for the NHS to successfully launch this cardio risk assessment program. -
New FDA Guidance on Antidiabetic Therapies
White Paper — December 11, 2009
Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.
